Big Pharma Reduces Investment Interest in Britain
Industry leaders express concern over regulatory climate and market conditions
Major pharmaceutical companies are showing signs of cooling interest in investing in Britain, citing concerns over regulatory hurdles, drug pricing pressures, and competitive disadvantages.
Industry analysts warn that without policy changes, the trend could impact innovation and future drug availability in the country.
Industry analysts warn that without policy changes, the trend could impact innovation and future drug availability in the country.
